Atlas Trials

A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Clinical trial NCT01503502 · UNKNOWN

Trial details

NCT number
NCT01503502
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Myelogenous Leukemia, Chronic
Start date
2011-08-01
Primary completion
2012-06-01
Enrollment
150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.